Inhibition of UDP-glucuronosyltransferase by 5'-O-amino acid and oligopeptide derivatives of uridine: structure-activity relationships. 1998

Z G Naydenova, and K C Grancharov, and D K Alargov, and E V Golovinsky, and I M Stanoeva, and L D Shalamanova, and I K Pajeva
Institue of Molecular Biology, Bulgarian Academy of Sciences, Sofia.

The inhibitory effect of a series of 5'-O-amino acid and oligopeptide derivatives of uridine on rat liver UDP-glucuronosyltransferase (UGT) activities was investigated using two assay systems. A quantitative structure-activity relationship (QSAR) study was performed. The compounds include a lipophilic residue linked to the nucleoside by a variable spacer. Moreover, half of the derivatives have two spacers linked to the uridine moiety. Compound 1, a serine derivative of isopropylideneuridine, was found to be the most potent inhibitor of both 4-nitrophenol (4-NP) and phenolphthalein (PPh) glucuronidation, with an I50 of 0.45 mM and 0.22 mM, respectively. Kinetic studies with this substance revealed a mixed type of inhibition towards 4-NP and UDP-glucuronic acid, with apparent Ki values of 150 microM and 120 microM, respectively. The dipeptide derivatives 11-14 exhibited a low activity against 4-NP conjugation. However, a marked suppression of PPh glucuronidation was found with compounds 11 and 13. Generally, compounds with two spacers are more inhibitory against the UGT activities studied. The QSAR analysis outlined the significance of the spacers with a minimum length of 5 atoms and lipophilic residues linked to them for the inhibitory effect of the compounds. The most significant contribution to this effect is given by the six-atom spacer for both 4-NP and PPh substrates. 4-NP converting UGT isoforms seem to respond more specifically to the inhibitors: a five-atom for the first and six-atom for the second spacer enhance binding to both 4-NP and PPh conjugating isoenzymes, while a long second spacer contributes to inhibitor binding to UGT isoforms only converting PPH.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008297 Male Males
D008862 Microsomes, Liver Closed vesicles of fragmented endoplasmic reticulum created when liver cells or tissue are disrupted by homogenization. They may be smooth or rough. Liver Microsomes,Liver Microsome,Microsome, Liver
D004151 Dipeptides Peptides composed of two amino acid units. Dipeptide
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D000596 Amino Acids Organic compounds that generally contain an amino (-NH2) and a carboxyl (-COOH) group. Twenty alpha-amino acids are the subunits which are polymerized to form proteins. Amino Acid,Acid, Amino,Acids, Amino
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D014453 Glucuronosyltransferase A family of enzymes accepting a wide range of substrates, including phenols, alcohols, amines, and fatty acids. They function as drug-metabolizing enzymes that catalyze the conjugation of UDPglucuronic acid to a variety of endogenous and exogenous compounds. EC 2.4.1.17. Glucuronyltransferase,UDP Glucuronosyltransferase,17 beta-Hydroxysteroid UDP-Glucuronosyltransferase,4-Nitrophenol-UDP-Glucuronosyltransferase,7-Hydroxycoumarin UDP Glucuronyltransferase,Androsterone UDP-Glucuronosyltransferase,Bilirubin UDP-Glucuronyltransferase,Estrogen UDP-Glucuronosyltransferase,Estrone Glucuronyltransferase,Glucuronic Transferase,Morphine Glucuronyltransferase,UDP Glucuronyl Transferase,UDP-Glucuronic Acid 3-O-beta-D-Galactosyl-D-Galactose Glucuronosyltransferase,p-Nitrophenyl UDP-Glucuronosyltransferase,17 beta Hydroxysteroid UDP Glucuronosyltransferase,4 Nitrophenol UDP Glucuronosyltransferase,7 Hydroxycoumarin UDP Glucuronyltransferase,Androsterone UDP Glucuronosyltransferase,Bilirubin UDP Glucuronyltransferase,Estrogen UDP Glucuronosyltransferase,Glucuronosyltransferase, UDP,Glucuronyl Transferase, UDP,Glucuronyltransferase, 7-Hydroxycoumarin UDP,Glucuronyltransferase, Estrone,Glucuronyltransferase, Morphine,Transferase, Glucuronic,Transferase, UDP Glucuronyl,UDP Glucuronic Acid 3 O beta D Galactosyl D Galactose Glucuronosyltransferase,UDP Glucuronyltransferase, 7-Hydroxycoumarin,UDP-Glucuronosyltransferase, 17 beta-Hydroxysteroid,UDP-Glucuronosyltransferase, Androsterone,UDP-Glucuronosyltransferase, Estrogen,UDP-Glucuronosyltransferase, p-Nitrophenyl,UDP-Glucuronyltransferase, Bilirubin,p Nitrophenyl UDP Glucuronosyltransferase
D014529 Uridine A ribonucleoside in which RIBOSE is linked to URACIL. Allo-Uridine,Allouridine,Allo Uridine

Related Publications

Z G Naydenova, and K C Grancharov, and D K Alargov, and E V Golovinsky, and I M Stanoeva, and L D Shalamanova, and I K Pajeva
April 1988, The Journal of biological chemistry,
Z G Naydenova, and K C Grancharov, and D K Alargov, and E V Golovinsky, and I M Stanoeva, and L D Shalamanova, and I K Pajeva
October 1991, Journal of pharmaceutical sciences,
Z G Naydenova, and K C Grancharov, and D K Alargov, and E V Golovinsky, and I M Stanoeva, and L D Shalamanova, and I K Pajeva
February 1952, The Journal of biological chemistry,
Z G Naydenova, and K C Grancharov, and D K Alargov, and E V Golovinsky, and I M Stanoeva, and L D Shalamanova, and I K Pajeva
January 1991, European journal of clinical pharmacology,
Z G Naydenova, and K C Grancharov, and D K Alargov, and E V Golovinsky, and I M Stanoeva, and L D Shalamanova, and I K Pajeva
January 1975, Journal of medicinal chemistry,
Z G Naydenova, and K C Grancharov, and D K Alargov, and E V Golovinsky, and I M Stanoeva, and L D Shalamanova, and I K Pajeva
August 2017, Drug metabolism and pharmacokinetics,
Z G Naydenova, and K C Grancharov, and D K Alargov, and E V Golovinsky, and I M Stanoeva, and L D Shalamanova, and I K Pajeva
February 1997, Biochemical pharmacology,
Z G Naydenova, and K C Grancharov, and D K Alargov, and E V Golovinsky, and I M Stanoeva, and L D Shalamanova, and I K Pajeva
April 1996, The Biochemical journal,
Z G Naydenova, and K C Grancharov, and D K Alargov, and E V Golovinsky, and I M Stanoeva, and L D Shalamanova, and I K Pajeva
November 1988, Biochimica et biophysica acta,
Z G Naydenova, and K C Grancharov, and D K Alargov, and E V Golovinsky, and I M Stanoeva, and L D Shalamanova, and I K Pajeva
August 1984, Biochemical pharmacology,
Copied contents to your clipboard!